Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diabetes and vascular complications: the role of endothelin and physical inactivity
2009-015602-18Phase 4Active
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Aug 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of bosentan in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Contribution of endothelin to leg baseline blood flow. Started Aug 2009; status: active.
02
Drugs
bosentan
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-015602-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015602-18.